Radiation Improves Intratumoral Gene Therapy for Induction of Cancer Vaccine in Murine Prostate Carcinoma

التفاصيل البيبلوغرافية
العنوان: Radiation Improves Intratumoral Gene Therapy for Induction of Cancer Vaccine in Murine Prostate Carcinoma
المؤلفون: Yu Wang, Nikoletta L. Kallinteris, Jeffrey D. Forman, Timothy C. Thompson, Jennifer L Wright, Malcolm S. Mitchell, Minzhen Xu, Samuel Tekyi-Mensah, Gilda G. Hillman, Xueqing Lu
المصدر: Human Gene Therapy. 14:763-775
بيانات النشر: Mary Ann Liebert Inc, 2003.
سنة النشر: 2003
مصطلحات موضوعية: Male, Genetic enhancement, medicine.medical_treatment, Genetic Vectors, Gene Expression, Injections, Intralesional, Radiation Dosage, Major histocompatibility complex, Cancer Vaccines, Adenoviridae, Interferon-gamma, Mice, Immune system, Antigen, Transduction, Genetic, Cell Line, Tumor, Histocompatibility Antigens, Genetics, medicine, Animals, Cytotoxic T cell, Interferon gamma, Molecular Biology, biology, Carcinoma, Histocompatibility Antigens Class II, Nuclear Proteins, Prostatic Neoplasms, Genetic Therapy, Antigens, Differentiation, B-Lymphocyte, Mice, Inbred C57BL, Radiation therapy, Trans-Activators, Cancer research, biology.protein, Molecular Medicine, Cancer vaccine, Plasmids, T-Lymphocytes, Cytotoxic, medicine.drug
الوصف: Our goal was to convert murine RM-9 prostate carcinoma cells in vivo into antigen-presenting cells capable of presenting endogenous tumor antigens and triggering a potent T-helper cell-mediated immune response essential for the generation of a specific antitumor response. We showed that generating the major histocompatibility complex (MHC) class I+/class II+/Ii- phenotype, within an established subcutaneous RM-9 tumor nodule, led to an effective immune response limiting tumor growth. This phenotype was created by intratumoral injection of plasmid cDNAs coding for interferon gamma, MHC class II transactivator, and an antisense reverse gene construct (RGC) for a segment of the gene for Ii protein (-92,97). While this protocol led to significant suppression of tumor growth, there were no disease-free survivors. Nevertheless, irradiation of the tumor nodule on the day preceding initiation of gene therapy yielded 7 of 16 mice that were disease-free in a long-term follow up of 57 days compared to 1 of 7 mice receiving radiotherapy alone. Mice receiving radiotherapy and gene therapy rejected challenge with parental RM-9 cells and demonstrated specific cytotoxic T-cell activity in their splenocytes but not the mouse cured by radiation alone. These data were reproduced in additional experiments and confirmed that tumor irradiation prior to gene therapy resulted in complete tumor regression and specific tumor immunity in more than 50% of the mice. Increasing the number of plasmid injections after tumor irradiation induced tumor regression in 70% of the mice. Administering radiation before this novel gene therapy approach, that creates an in situ tumor vaccine, holds promise for the treatment of human prostate carcinoma.
تدمد: 1557-7422
1043-0342
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f34781164199dd7945716e9de354f127
https://doi.org/10.1089/104303403765255156
حقوق: CLOSED
رقم الأكسشن: edsair.doi.dedup.....f34781164199dd7945716e9de354f127
قاعدة البيانات: OpenAIRE